Rausch, C., Borthakur, G., Haddad, F., Chien, K., Hammond, D., Montalban-Bravo, G., Pemmaraju, N., Masarova, L., Yilmaz, M., Andreeff, M., Jabbour, E., Burger, J., Jain, N., Ravandi, F., Kadia, T. (2025). Cladribine-based low-intensity therapy is safe and effective in patients with newly diagnosed Acute Myeloid Leukemia (AML) and renal impairment. Blood. https://doi.org/10.1182/blood-2025-3457